Intermittent targeted therapies and stochastic evolution in patients affected by chronic myeloid leukemia

Risultato della ricerca: Articlepeer review

4 Citazioni (Scopus)


Front line therapy for the treatment of patients affected by chronic myeloid leukemia (CML) is based on the administration of tyrosine kinase inhibitors, namely imatinib or, more recently, axitinib. Although imatinib is highly effective and represents an example of a successful molecular targeted therapy, the appearance of resistance is observed in a proportion of patients, especially those in advanced stages. In this work, we investigate the appearance of resistance in patients affected by CML, by modeling the evolutionary dynamics of cancerous cell populations in a simulated patient treated by an intermittent targeted therapy. We simulate, with the Monte Carlo method, the stochastic evolution of initially healthy cells to leukemic clones, due to genetic mutations and changes in their reproductive behavior. We first present the model and its validation with experimental data by considering a continuous therapy. Then, we investigate how fluctuations in the number of leukemic cells affect patient response to the therapy when the drug is administered with an intermittent time scheduling. Here we show that an intermittent therapy (IT) represents a valid choice in patients with high risk of toxicity, despite an associated delay to the complete restoration of healthy cells. Moreover, a suitably tuned IT can reduce the probability of developing resistance.
Lingua originaleEnglish
pagine (da-a)054032-1-054032-15
Numero di pagine15
RivistaJournal of Statistical Mechanics: Theory and Experiment
Stato di pubblicazionePublished - 2016

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.3100.3109???
  • ???subjectarea.asjc.2600.2613???
  • ???subjectarea.asjc.1800.1804???


Entra nei temi di ricerca di 'Intermittent targeted therapies and stochastic evolution in patients affected by chronic myeloid leukemia'. Insieme formano una fingerprint unica.

Cita questo